Opthea to host investor days in New York, Australia

Opthea (OPT) will host an Investor Day on Tuesday, January 28, 2025 at 1:30 PM ET in New York City, followed by presentations in Sydney and Melbourne in early February. As the Company prepares for the anticipated topline data readout of its two pivotal trials, COAST in early CY Q2 2025 and ShORe in mid-CY 2025, the New York in-person event and live webcast will feature presentations from international retina thought leader Charles C. Wykoff, MD, PhD and Opthea’s senior management team, including Chief Commercial Officer Mike Campbell. Opthea’s Investor Day will highlight the following: The continued medical need for better vision outcomes in wet AMD and the opportunity for sozinibercept to transform patient lives with superior vision gains. New insights on the commercial potential and commercial readiness plans for sozinibercept in combination with standard-of-care anti-VEGF-A therapies. It is expected that the presentations, followed by a question-and-answer session, will conclude by approximately 3:00 PM ET. Following the live webcast, a replay will be made available on the Company’s website. The Company’s senior management will also host in-person investor presentations in Sydney on Monday February 3 at 4:30 PM AEDT and Melbourne on Wednesday February 5 at 4:30 PM AEDT.